MA45154B1 - Procédés de préparation d'oligomères - Google Patents

Procédés de préparation d'oligomères

Info

Publication number
MA45154B1
MA45154B1 MA45154A MA45154A MA45154B1 MA 45154 B1 MA45154 B1 MA 45154B1 MA 45154 A MA45154 A MA 45154A MA 45154 A MA45154 A MA 45154A MA 45154 B1 MA45154 B1 MA 45154B1
Authority
MA
Morocco
Prior art keywords
oligomer
oligomers
processes
preparation
scaling
Prior art date
Application number
MA45154A
Other languages
English (en)
Other versions
MA45154A (fr
Inventor
Bao Cai
Mitchell MARTINI
Ross SHIMABUKU
Katie THOMAS
Diane Elizabeth Frank
Richard K. Bestwick
Original Assignee
Sarepta Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics, Inc. filed Critical Sarepta Therapeutics, Inc.
Publication of MA45154A publication Critical patent/MA45154A/fr
Publication of MA45154B1 publication Critical patent/MA45154B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

L'invention concerne des procédés de préparation d'un oligomère (par exemple, un oligomère morpholino). Les procédés de synthèse décrits dans l'invention peuvent être avantageux pour la mise à l'échelle de la synthèse d'oligomères tout en maintenant le rendement global et la pureté d'un oligomère synthétisé.
MA45154A 2016-05-24 2017-05-24 Procédés de préparation d'oligomères MA45154B1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662341049P 2016-05-24 2016-05-24
US201662357153P 2016-06-30 2016-06-30
US201662357166P 2016-06-30 2016-06-30
US201662357072P 2016-06-30 2016-06-30
US201662356923P 2016-06-30 2016-06-30
US201762508256P 2017-05-18 2017-05-18
PCT/US2017/034235 WO2017205496A1 (fr) 2016-05-24 2017-05-24 Procédés de préparation d'oligomères
EP17731336.8A EP3464305B1 (fr) 2016-05-24 2017-05-24 Procédés de préparation d'oligomères

Publications (2)

Publication Number Publication Date
MA45154A MA45154A (fr) 2019-04-10
MA45154B1 true MA45154B1 (fr) 2024-11-29

Family

ID=59078165

Family Applications (2)

Application Number Title Priority Date Filing Date
MA45154A MA45154B1 (fr) 2016-05-24 2017-05-24 Procédés de préparation d'oligomères
MA049775A MA49775A (fr) 2016-05-24 2017-05-24 Procédés de préparation d'oligomères morpholino de phosphorodiamidate

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA049775A MA49775A (fr) 2016-05-24 2017-05-24 Procédés de préparation d'oligomères morpholino de phosphorodiamidate

Country Status (21)

Country Link
US (2) US10875880B2 (fr)
EP (2) EP3564248A1 (fr)
JP (2) JP7008642B2 (fr)
KR (1) KR102506298B1 (fr)
CN (1) CN109563114B (fr)
AU (1) AU2017269355B2 (fr)
BR (2) BR112018074346B1 (fr)
CA (1) CA3025339A1 (fr)
CO (1) CO2018013838A2 (fr)
DK (1) DK3464305T3 (fr)
ES (1) ES2993738T3 (fr)
FI (1) FI3464305T3 (fr)
HR (1) HRP20241428T1 (fr)
IL (1) IL263149B2 (fr)
MA (2) MA45154B1 (fr)
MD (1) MD3464305T2 (fr)
MX (2) MX2021008539A (fr)
SA (1) SA518400500B1 (fr)
SG (1) SG10202101830WA (fr)
TW (2) TWI738784B (fr)
WO (1) WO2017205496A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
US10947533B2 (en) 2016-05-24 2021-03-16 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
CA3024456A1 (fr) 2016-05-24 2017-11-30 Sarepta Therapeutics, Inc. Procedes de preparation d'oligomeres morpholino de phosphorodiamidate
MD3464306T2 (ro) * 2016-05-24 2024-08-31 Sarepta Therapeutics Inc Procedee de preparare a oligomerilor morfolino fosforodiamidați
BR112018074346B1 (pt) 2016-05-24 2023-01-03 Sarepta Therapeutics, Inc. Composto oligomérico e processo para preparar um composto oligomérico
KR102523527B1 (ko) * 2016-06-30 2023-04-20 사렙타 쎄러퓨틱스 인코퍼레이티드 포스포로디아미데이트 모르폴리노 올리고머의 제조 방법
KR102523522B1 (ko) * 2016-06-30 2023-04-20 사렙타 쎄러퓨틱스 인코퍼레이티드 포스포로디아미데이트 모르폴리노 올리고머의 제조 방법
WO2019060862A1 (fr) * 2017-09-25 2019-03-28 Sarepta Therapeutics, Inc. Procédés de préparation d'oligomères morpholino phosphorodiamidate par l'intermédiaire d'une synthèse à flux rapide
JP2021521794A (ja) * 2018-04-26 2021-08-30 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート
JP2026506527A (ja) * 2023-02-01 2026-02-25 アルナイラム ファーマシューティカルズ， インコーポレイテッド ６員環含有オリゴマー

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
WO1986005519A1 (fr) 1985-03-15 1986-09-25 James Summerton Reactif et procede d'analyse de polynucleotides
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
WO1990002749A1 (fr) 1988-09-01 1990-03-22 Forskningscenter Risø Procede de synthese de peptides et support solide de realisation dudit procede
CN1046724C (zh) 1993-12-29 1999-11-24 藤泽药品工业株式会社 吡唑并吡啶化合物、含有它们的药物组合物、及其制法与用途
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
US7053207B2 (en) 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
US6784291B2 (en) 2000-05-04 2004-08-31 Avi Biopharma, Inc. Splice-region antisense composition and method
CA2459347C (fr) 2001-09-04 2012-10-09 Exiqon A/S Compositions d'acides nucleiques bloques et leurs utilisations
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
AU2003287464A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. 2'-fluoro substituted oligomeric compounds and compositions for use in gene modulations
US7759513B2 (en) 2003-02-21 2010-07-20 Nigu Chemie Gmbh Photolabile protective groups for improved processes to prepare oligonucleotide arrays
EP2933332A1 (fr) 2004-06-28 2015-10-21 The University Of Western Australia Oligonucléotides antisens permettant d'induire un saut d'exon et leurs procédés d'utilisation
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
PL2735568T3 (pl) * 2006-05-10 2018-02-28 Sarepta Therapeutics, Inc. Analogi oligonukleotydowe mające kationowe połączenia pomiędzy podjednostkami
US9371348B2 (en) 2006-11-27 2016-06-21 The Trustees Of The University Of Pennsylvania Photocleavable oligonucleotide and uses thereof
RU2606627C2 (ru) 2007-11-15 2017-01-10 Серепта Терапьютикс,Инк. Способ синтеза морфолиновых олигомеров
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
BR122020021379B1 (pt) 2008-10-24 2021-05-11 Sarepta Therapeutics, Inc. oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular
CA2758189C (fr) 2009-04-10 2020-12-29 Association Institut De Myologie Oligonucleotides antisens tricyclo-adn, compositions, et methodes de traitement de maladies
TR201816523T4 (tr) 2009-11-12 2018-11-21 Univ Western Australia Patolojilerin tedavisine yönelik antisens moleküller ve yöntemler.
TWI463423B (zh) 2010-05-28 2014-12-01 Poynt Corp 用以針對基於三維形狀之廣告系統使用位置資訊的方法
KR20200133284A (ko) 2010-05-28 2020-11-26 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
ES2607603T3 (es) 2010-09-30 2017-04-03 Nippon Shinyaku Co., Ltd. Derivado de ácido morfolino nucleico
EP2672977A1 (fr) * 2011-02-08 2013-12-18 The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System Oligonucléotides antisens
EP2748176B1 (fr) 2011-08-23 2019-04-17 The Royal Institution for the Advancement of Learning / McGill University Marqueurs ioniques pour la synthèse d'oligoribonucléotides
PL2581448T3 (pl) 2011-10-13 2015-08-31 Association Inst De Myologie Tricyklo-tiofosforanowy DNA
HK1201514A1 (en) 2011-11-18 2015-09-04 Sarepta Therapeutics, Inc. Functionally-modified oligonucleotides and subunits thereof
JP6496549B2 (ja) * 2011-11-30 2019-04-03 サレプタ セラピューティクス， インコーポレイテッド 脊髄性筋萎縮症における誘発されたエクソン包含
CA2861247C (fr) * 2011-12-28 2021-11-16 Nippon Shinyaku Co., Ltd. Acide nucleique antisens
WO2013128281A1 (fr) 2012-02-28 2013-09-06 Population Genetics Technologies Ltd Procédé de fixation d'une contre-séquence à un échantillon d'acides nucléiques
CN102702265A (zh) * 2012-05-14 2012-10-03 天津特安化学科技有限公司 一种固相合成磷酰二胺吗啉代寡核苷酸及方法
US20140315977A1 (en) * 2013-03-14 2014-10-23 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
CN110218727A (zh) * 2013-03-14 2019-09-10 萨勒普塔医疗公司 用于治疗肌营养不良的外显子跳跃组合物
US20140329762A1 (en) 2013-03-15 2014-11-06 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
DK3015467T3 (da) 2013-05-24 2025-02-10 Ajinomoto Kk Morpholino-oligonukleotidfremstillingsfremgangsmåde
BR112018074346B1 (pt) 2016-05-24 2023-01-03 Sarepta Therapeutics, Inc. Composto oligomérico e processo para preparar um composto oligomérico
CA3024456A1 (fr) 2016-05-24 2017-11-30 Sarepta Therapeutics, Inc. Procedes de preparation d'oligomeres morpholino de phosphorodiamidate
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
US10947533B2 (en) 2016-05-24 2021-03-16 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
MD3464306T2 (ro) * 2016-05-24 2024-08-31 Sarepta Therapeutics Inc Procedee de preparare a oligomerilor morfolino fosforodiamidați
PT3554552T (pt) 2016-12-19 2022-10-03 Sarepta Therapeutics Inc Conjugados de oligómero de skipping de exão para distrofia muscular
KR102810425B1 (ko) 2016-12-19 2025-05-21 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
KR20240006023A (ko) 2016-12-19 2024-01-12 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии

Also Published As

Publication number Publication date
HRP20241428T1 (hr) 2025-01-03
US20200040020A1 (en) 2020-02-06
AU2017269355A1 (en) 2019-01-17
BR112018074346B1 (pt) 2023-01-03
AU2017269355B2 (en) 2021-04-15
MX384727B (es) 2025-03-14
MA49775A (fr) 2020-06-10
CN109563114A (zh) 2019-04-02
MA45154A (fr) 2019-04-10
KR20190015311A (ko) 2019-02-13
ES2993738T3 (en) 2025-01-08
KR102506298B1 (ko) 2023-03-06
CN109563114B (zh) 2022-08-12
EP3464305B1 (fr) 2024-08-21
IL263149A (en) 2019-01-31
SG10202101830WA (en) 2021-04-29
IL263149B2 (en) 2023-05-01
SA518400500B1 (ar) 2022-09-01
EP3464305A1 (fr) 2019-04-10
EP3564248A1 (fr) 2019-11-06
TWI801843B (zh) 2023-05-11
MD3464305T2 (ro) 2025-01-31
MX2018014472A (es) 2019-05-23
US20210198296A1 (en) 2021-07-01
DK3464305T3 (da) 2024-10-28
JP7008642B2 (ja) 2022-01-25
JP2019518832A (ja) 2019-07-04
US10875880B2 (en) 2020-12-29
TWI738784B (zh) 2021-09-11
WO2017205496A1 (fr) 2017-11-30
US11384105B2 (en) 2022-07-12
IL263149B1 (en) 2023-01-01
TW202200599A (zh) 2022-01-01
TW201806962A (zh) 2018-03-01
BR122022014984B1 (pt) 2024-03-05
CA3025339A1 (fr) 2017-11-30
CO2018013838A2 (es) 2019-01-18
MX2021008539A (es) 2022-10-18
JP2021176967A (ja) 2021-11-11
BR112018074346A2 (pt) 2019-03-06
FI3464305T3 (fi) 2024-10-30

Similar Documents

Publication Publication Date Title
MA45155B1 (fr) Procédés de préparation d'oligomères morpholino de phosphorodiamidate
MA45154B1 (fr) Procédés de préparation d'oligomères
MA47970B1 (fr) Composé inhibiteur de jak à base d'imidazo-pipéridine fusionnée
MX2018014123A (es) Procesos para preparar oligomeros de morfolino fosforodiamidato.
ZA202403308B (en) An efficient new process for synthesis of 2-amino-5-chloro-n-,3-dimethylbenzamide
WO2016141296A8 (fr) Inhibiteurs de kinases tricycliques de melk et procédés d'utilisation
SA518400463B1 (ar) عمليات لتحضير أوليجومرات فوسفوروداي أميدات مورفولينو
NO20014194L (no) Regioselektiv syntese av DTPA-derivater
WO2018039629A3 (fr) Acides nucléiques sphériques micellaires obtenus à partir de matrices thermosensibles sans trace
MA68842B1 (fr) Procédé de conjugaison de cys-mabs
WO2017112809A8 (fr) Système et procédé de synthèse de peptides gap en phase solution
MA46548A (fr) Fsh pour le traitement de l'infertilité
MX2021007505A (es) Síntesis de 3-metil-1,2,4-tiadiazol-5-carbohidrazida o de su forma deuterada con metil-d3.
MY140739A (en) 2, 6-quinolinyl derivatives, processes for preparing them and their uses
MY195119A (en) Method For Purifying Isobutene from a C4 Stream and Process System Therefor
MX2018014160A (es) Procesos para preparar oligomeros de morfolino fosforodiamidato.
MX395643B (es) Proceso para preparar fenilalcanos sustituidos.
FR3056398B1 (fr) Ventouse de massage
NO20060417L (no) Fremgangsmate til fremstilling av 1-okten fra krakk-C4
EP4081203A4 (fr) Spectroscopie ftnir pour le suivi de la réaction de synthèse de l'acrylamide
CL2014001043A1 (es) Procedimiento para preparar un compuesto intermediario en la ruta de sintesis de tmc 435, inhibidor de proteasa, útil en el tratamiento de la hepatitis c.
MA50149A (fr) Procedé pour la préparation de l'anneau de pipérazine pour la synthèse de pyrazinocarbazole
WO2017189415A8 (fr) Préparation à activité spécifique élevée de tétrafluoroborate f -18
DE60329721D1 (de) Regiospezifische synthese von nikotinderivaten
WO2015159170A3 (fr) Procédé amélioré pour la synthèse de 1-(4-méthoxyphényl) éthylamine et ses isomères